Scinai Immunotherapeutics Ltd. SEC filings

Filings

Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.

1. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNI3d

   Scinai Immunotherapeutics closes $4M financing

   • $4.0 million financing through private placement
   • Warrant inducement included
   • Press release dated October 16, 2026
2. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNI4d

   Scinai Immunotherapeutics Ltd. raises capital

   • Private placement of 2,458,334 ADSs at $1.20 per ADS
   • Warrants to buy 3,687,501 ADSs at $1.20 per ADS
   • Placement agent fee up to 7% of gross proceeds
3. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNI6d

   Scinai expands CDMO business

   • $5.1 million development and clinical manufacturing agreement
   • Committed customer orders up 300% to $7.6 million
   • Potential additional $5.85 million in 2027-2028 manufacturing
4. ROUTINEEFFECTScinai Immunotherapeutics Ltd.SCNIOct 5

   Scinai Immunotherapeutics Ltd. filed Form F-1.

   • Filed on 2026-10-05.
   • Effectiveness date: October 5, 2026.
   • Form: F-1.
5. NOTABLEF-1Scinai Immunotherapeutics Ltd.SCNISep 24

   Securities offering

6. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNISep 21

   Foreign issuer report

7. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNISep 8

   Foreign issuer report

8. ROUTINEPOS AMScinai Immunotherapeutics Ltd.SCNIAug 27

   POS AM filing

9. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNIAug 26

   Foreign issuer report

10. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNIAug 19

    Foreign issuer report

11. ROUTINESCHEDULE 13G/AScinai Immunotherapeutics Ltd.SCNIJul 9

    Ownership stake disclosure by LCK JNK 1 LLC (amended)

    LCK JNK 1 LLC, filed by

12. ROUTINESCHEDULE 13G/AScinai Immunotherapeutics Ltd.SCNIJul 1

    Ownership stake disclosure by Daniel E. Stone (amended)

    Daniel E. Stone, filed by

13. ROUTINE4Scinai Immunotherapeutics Ltd.SCNIJun 18

    2 insider filings

    Mark Germain, insider filing for SCNI

    Show all 2

    • 4Insider filing for SCNIJun 18
    • 4Insider filing for SCNIJun 18

    Mark Germain, reporting

14. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNIJun 17

    Foreign issuer report

15. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNIJun 15

    Foreign issuer report

16. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNIJun 8

    Foreign issuer report

17. ROUTINEEFFECTScinai Immunotherapeutics Ltd.SCNIMay 20

    Registration declared effective

18. ROUTINE424B3Scinai Immunotherapeutics Ltd.SCNIMay 19

    Securities offering

19. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNIMay 12

    Foreign issuer report

20. ROUTINEF-3Scinai Immunotherapeutics Ltd.SCNIMay 8

    Securities offering

21. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNIMay 8

    Foreign issuer report

22. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNIApr 27

    Foreign issuer report

23. NOTABLE20-FScinai Immunotherapeutics Ltd.SCNIApr 1

    Annual report

24. ROUTINE3Scinai Immunotherapeutics Ltd.SCNIMar 26

    Elad Mark, new insider at SCNI

    Elad Mark, reporting

25. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNIMar 23

    Foreign issuer report

26. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNIMar 19

    Foreign issuer report

27. ROUTINE3Scinai Immunotherapeutics Ltd.SCNIMar 18

    7 insider filings

    Yael Margolin, new insider at SCNI

    Show all 7

    • 3New insider at SCNIMar 18
    • 3New insider at SCNIMar 18
    • 3New insider at SCNIMar 18
    • 3New insider at SCNIMar 18
    • 3New insider at SCNIMar 18
    • 3New insider at SCNIMar 18
    • 3New insider at SCNIMar 18

    Yael Margolin, reporting

28. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNIFeb 25

    Foreign issuer report

29. ROUTINESCHEDULE 13G/AScinai Immunotherapeutics Ltd.SCNIFeb 17

    Ownership stake disclosure by Daniel E. Stone (amended)

    Daniel E. Stone, filed by

30. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNIFeb 17

    Foreign issuer report

31. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNIDec 23, 2025

    Foreign issuer report

32. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNIDec 2, 2025

    Foreign issuer report

33. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNINov 13, 2025

    Scinai Immunotherapeutics Ltd. (SCNI) filed a Form 6-K reporting on the successful completion of its Phase 3 clinical trial for its lead cancer immunotherapy candidate, demonstrating significant improvements in overall survival for patients.

34. ROUTINE6-KScinai Immunotherapeutics Ltd.SCNINov 13, 2025

    Scinai Immunotherapeutics Ltd. (SCNI) filed a Form 6-K to report the successful completion of its Phase 3 clinical trial for its lead cancer immunotherapy candidate, demonstrating significant efficacy and safety.

35. ROUTINES-8Scinai Immunotherapeutics Ltd.SCNINov 12, 2025

    Employee stock plan registration

Older filings on EDGAR